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CONTROL OF VANCOMYCIN-RESISTANT ENTEROCOCCUS IN HEALTH CARE
FACILITIES IN A REGION
BELINDA E. OSTROWSKY, M.D., M.P.H., WILLIAM E. TRICK, M.D., ANNETTE H. SOHN, M.D., STEPHEN B. QUIRK, M.P.P.,
STACEY HOLT, M.M.SC., LORETTA A. CARSON, M.S., BERTHA C. HILL, B.S., MATTHEW J. ARDUINO, PH.D.,
MATTHEW J. KUEHNERT, M.D., AND WILLIAM R. JARVIS, M.D.

ABSTRACT
Background In late 1996, vancomycin-resistant enterococci were first detected in the Siouxland region
of Iowa, Nebraska, and South Dakota. A task force was
created, and in 1997 the assistance of the Centers for
Disease Control and Prevention was sought in assessing the prevalence of vancomycin-resistant enterococci in the region’s facilities and implementing recommendations for screening, infection control, and
education at all 32 health care facilities in the region.
Methods The infection-control intervention was
evaluated in October 1998 and October 1999. We performed point-prevalence surveys, conducted a case–
control study of gastrointestinal colonization with
vancomycin-resistant enterococci, and compared infection-control practices and screening policies for
vancomycin-resistant enterococci at the acute care
and long-term care facilities in the Siouxland region.
Results Perianal-swab samples were obtained from
1954 of 2196 eligible patients (89 percent) in 1998 and
1820 of 2049 eligible patients (89 percent) in 1999.
The overall prevalence of vancomycin-resistant enterococci at 30 facilities that participated in all three years
of the study decreased from 2.2 percent in 1997 to 1.4
percent in 1998 and to 0.5 percent in 1999 (P<0.001
by chi-square test for trend). The number of facilities
that had had at least one patient with vancomycinresistant enterococci declined from 15 in 1997 to 10
in 1998 to 5 in 1999. At both acute care and long-term
care facilities, the risk factors for colonization with vancomycin-resistant enterococci were prior hospitalization and treatment with antimicrobial agents. Most
of the long-term care facilities screened for vancomycin-resistant enterococci (26 of 28 in 1998 [93 percent] and 23 of 25 in 1999 [92 percent]) and had infection-control policies to prevent the transmission
of vancomycin-resistant enterococci (22 of 25 [88 percent] in 1999). All four acute care facilities had screening and infection-control policies for vancomycinresistant enterococci in 1998 and 1999.
Conclusions An active infection-control intervention, which includes the obtaining of surveillance
cultures and the isolation of infected patients, can reduce or eliminate the transmission of vancomycinresistant enterococci in the health care facilities of a
region. (N Engl J Med 2001;344:1427-33.)
Copyright © 2001 Massachusetts Medical Society.

D

URING the past decade, vancomycinresistant enterococci have emerged and become endemic at many health care facilities
in the United States.1-6 A major impediment to control is the large, unrecognized population
of patients who are colonized with vancomycin-resistant enterococci and who thus can serve as a reservoir
for transmission.7-9 Colonization with vancomycinresistant enterococci has been associated with progression to infection.8 Studies suggest that once
vancomycin-resistant enterococci are introduced in
a facility, and particularly after they have spread to
multiple patients or wards, control is very difficult.6-8
Between December 1996 and April 1997, the number of isolates of vancomycin-resistant enterococci
increased from 0 to 63 at health care facilities in the
Siouxland region of Iowa, Nebraska, and South Dakota, which has a population of 135,000. A task force
was formed, and in July 1997 the Hospital Infections
Program of the Centers for Disease Control and Prevention (CDC) was invited to assist in an investigation. The prevalence of vancomycin-resistant enterococci at the 32 facilities (4 acute care and 28 long-term
care facilities) in the region was determined, and risk
factors for vancomycin-resistant enterococci were assessed.10 On the basis of these findings, an intervention
program was initiated. We returned on October 5,
1998, and October 25, 1999, to determine the prevalence of gastrointestinal colonization with vancomycin-resistant enterococci 14 and 26 months, respectively, after the initial prevalence survey and to evaluate
the effect of the intervention.
METHODS
The Task Force
In spring 1997, a meeting with representatives of health care
facilities in the Siouxland region of Iowa, Nebraska, and South
Dakota was held to discuss the sudden increase in the number of
isolates of vancomycin-resistant enterococci at these facilities, and
a task force was formed that included public health workers and
personnel from acute care and long-term care facilities. On the
basis of the initial results,10 a strategy to decrease the transmission

From the Hospital Infections Program, National Center for Infectious
Diseases (B.E.O., W.E.T., A.H.S., S.H., L.A.C., B.C.H., M.J.A., M.J.K.,
W.R.J.), and the Epidemic Intelligence Service, Division of Applied Public
Health Training, Epidemiology Program Office (B.E.O., W.E.T., A.H.S.,
M.J.K.), Centers for Disease Control and Prevention, Atlanta; and the
Siouxland District Health Department, Sioux City, Iowa (S.B.Q.). Address
reprint requests to Dr. Ostrowsky at the Medical College of Virginia Campus of Virginia Commonwealth University, Epidemiology and Infection
Control Unit, 1200 E. Broad St., West Hospital, East Wing Rm. 202B,
P.O. Box 980019, Richmond, VA 23298, or at bostrow@hsc.vcu.edu.
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of vancomycin-resistant enterococci was developed. The guidelines
of the task force11 were adapted from the CDC recommendations12
(Table 1). In April 1998, after review by the Hospital Infections
Program of the CDC and the Iowa Department of Health, the
guidelines were disseminated to all 32 health care facilities in the
Siouxland region.
Study Participants
In collaboration with the Siouxland District Health Department,
the task force, the state health departments of the three states involved, and the Indian Health Service, we invited the same 32 facilities in the region that took part in the 1997 study to participate
in the 1998 and 1999 studies.10 Eligible participants included all
nonpsychiatric inpatients who were 18 years of age or older. All
samples were collected by using premoistened swabs during three
successive days in both 1998 and 1999. Each patient was assigned
a number by the facility personnel and was not identified by name.
At the time of sample collection, oral consent was obtained.
Microbiologic Methods
A perianal swab, defined as a swab taken from the anal verge,
without rectal insertion, was obtained from all participants except
those with a colostomy or ileostomy stoma. Swabs from the latter

TABLE 1. GUIDELINES

INTERVENTION

Screening (by the culture of
perianal swabs)
On admission

At discharge
At other times
At time at which termination
of precautions is considered
Isolation and infection-control
precautions
Room assignment

Vancomycin-resistant enterococci status
Barrier precautions
Hand washing
Care of equipment
Education
Communication within facilities

patients were obtained from the junction of the epidermal and the
mucosal surfaces. All swabs were streaked onto bile esculin azide
with agar medium containing 6 µg of vancomycin per milliliter
(Becton Dickinson, Cockeysville, Md.) and incubated at 35°C for
48 hours. Colonies with morphologic features consistent with those
of enterococcus were transferred to blood–agar slants and transported to the CDC for microbiologic confirmation as enterococcus
and identification of the species,13 vancomycin-susceptibility testing,14 and molecular typing by pulsed-field gel electrophoresis.15
Isolates of vancomycin-resistant enterococci that were obtained during our surveys in 1998 and 1999 were compared with isolates
obtained during the initial survey in 1997 and with isolates obtained in late 1996 and 1997 that were requested in 1998 from
three medical centers within 160 to 480 km (100 to 300 mi) of
Sioux City, Iowa.
Epidemiologic Studies
In October 1998, a case–control study was conducted to assess
risk factors for gastrointestinal colonization with vancomycin-resistant enterococci. A patient was defined as any patient in a health
care facility of the Siouxland District Health Department who was
found to have gastrointestinal colonization with vancomycin-resistant enterococci during the point-prevalence survey. Control pa-

FOR THE CARE OF PATIENTS WITH VANCOMYCIN-RESISTANT
IN ACUTE CARE AND LONG-TERM CARE FACILITIES.*

ENTEROCOCCI WHO ARE

ACUTE CARE FACILITY

LONG-TERM CARE FACILITY

Patients who are transferred from acute care facilities outside the community

Patients who are admitted from acute care facilities whose
vancomycin-resistant enterococci status is unknown
should be evaluated for risk factors† and screened if appropriate; contact precautions should be implemented
until final results are known
No recommendations

Not recommended for patients who are being discharged
to long-term care facilities, if stay was less than 72 hr
and patient did not receive antimicrobial agents
Patients at high risk (if indicated)†
Follow CDC recommendations12‡

Private or with other patients positive for vancomycinresistant enterococci
System of identifying the records of patients with infection
or colonization
Use of gloves for direct patient contact; use of gowns for
substantial contact with patient and patient’s body fluids
Health care workers, patients, and visitors
Dedicated use of noncritical equipment; cleaning or disinfecting of equipment with approved disinfectants
Educational materials provided for health care workers,
patients, and visitors
Vancomycin-resistant enterococci status of patient indicated orally and written on transfer sheets

Patients at high risk (if indicated)†
Follow CDC recommendations12‡

Private or with other patients positive for vancomycinresistant enterococci; can share room with a patient
negative for vancomycin-resistant enterococci if both
patients meet specific criteria§
System of identifying the records of patients with infection
or colonization
Use of gloves for direct patient contact; use of gowns for
substantial contact with patient and patient’s body fluids
Health care workers, patients, and visitors
Dedicated use of noncritical equipment; cleaning or disinfecting of equipment with approved disinfectants
Educational materials provided for health care workers, patients, and visitors
Vancomycin-resistant enterococci status of patient indicated orally and written on transfer sheets

*Adapted from the recommendations of the Siouxland Vancomycin-Resistant Enterococci Task Force.11
†Patients at high risk are patients who have been hospitalized longer than 72 hours, those with clinically significant underlying medical conditions (patients undergoing dialysis, patients with cancer, and transplant recipients), those in intensive care, and those undergoing prolonged treatment with antimicrobial agents or with invasive devices.
‡A change in health status or treatment with antimicrobial agents may warrant the reestablishment of precautions.
§The following criteria (listed in order of importance) must be met: roommate cannot be immunosuppressed or have broken skin or renal failure; roommate and patient who is positive for vancomycin-resistant enterococci must be coherent and able to wash their hands and observe other infection-control
practices; patient who is positive for vancomycin-resistant enterococci cannot have diarrhea, urinary incontinence, or draining wound.
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tients without gastrointestinal colonization with vancomycin-resistant enterococci were randomly selected from facilities that had
patients with colonization. Patients and controls were compared
with regard to demographic characteristics, clinical and functional
status, prior admission to a health care facility, and prior treatment with antimicrobial agents.8,9,16-19
Site Visits and Infection-Control Assessment
In 1998, site visits were performed at acute care and long-term
care facilities to review the policies of each facility regarding the
control of vancomycin-resistant enterococcal infections and compare them with the answers to previously distributed institutional
questionnaires. In 1999, a follow-up infection-control questionnaire
was administered. The rates of screening of patients for vancomycin-resistant enterococci, isolation or grouping (“cohorting”) of
patients colonized or infected with vancomycin-resistant enterococci, and infection-control policies in 1997, 1998, and 1999 were
compared.
Use of Antimicrobial Agents
On the day of the site visit to a long-term care facility, staff members were asked to provide the number of patients during the previous week who had been prescribed antimicrobial agents. One
acute care facility in Sioux City was also asked to provide the number of patients admitted and the number prescribed vancomycin in
1997 (before the intervention) and 1998 (after the intervention).
Statistical Analysis
Data were collected on standardized forms, entered into the
computer, and analyzed with use of Epi Info (version 6.03, CDC,
Atlanta) and SAS software (version 6.12, SAS Institute, Cary, N.C.).
The prevalence rates for each year were compared with the use of
a crude chi-square test, Mantel–Haenszel adjusted chi-square test,
and a chi-square test for trend. For the case–control study, categorical variables were compared with the use of the Mantel–Haenszel
chi-square test, with each facility considered as a stratum. Odds
ratios and 95 percent confidence intervals were calculated.

RESULTS
Characteristics of the Facilities and Patients

All 32 health care facilities located within 80 km
(50 mi) of Sioux City participated in the survey of
the prevalence of vancomycin-resistant enterococci in
1998, and 30 (4 acute care and 26 long-term care
facilities) participated in 1999. Of the 32 health care
facilities, 13 of the 28 long-term care facilities (46

OF

TYPE

percent) and 2 of the 4 acute care facilities (50 percent) were located in the Sioux City metropolitan area. Two of the four acute care facilities were referral
centers for regional community hospitals; these two
facilities had intensive care, burn, and cardiothoracicsurgery units.
We collected swabs from 1954 of 2196 eligible patients in 1998 (89 percent) and 1820 of 2049 eligible
patients in 1999 (89 percent). The overall and facilityspecific rates of participation were similar in 1997,
1998, and 1999 (Table 2). Infection-control personnel in the acute care facilities reported that patients
in obstetrics and surgery wards frequently declined
to participate or were unavailable because the day of
the survey was the day of their procedure. Eleven of
the long-term care facilities in both 1998 and 1999
had participation rates of 100 percent.
Prevalence of Vancomycin-Resistant Enterococci

Twenty-nine patients were identified as being colonized with vancomycin-resistant enterococci in 1998
(overall prevalence, 1.5 percent) and nine in 1999
(overall prevalence, 0.5 percent). All isolates were Enterococcus faecium, with minimal inhibitory concentrations of vancomycin of at least 256 µg per milliliter. In the 30 facilities that participated in all three
years of the survey, there were 40 patients with colonization with vancomycin-resistant enterococci in 1997
(2.2 percent), 26 in 1998 (1.4 percent), and 9 in
1999 (0.5 percent). The two facilities that chose not
to participate in 1999 had no patients who were colonized with vancomycin-resistant enterococci in 1997
and had three patients who were colonized in 1998.
When we compared the prevalence rates in 1997 with
those in 1998 and with those in 1999, the overall
rates and the facility-specific rates had decreased (Table 3).
In 1997, 15 facilities (3 acute care and 12 longterm care facilities) had at least one patient with vancomycin-resistant enterococci. In contrast, 10 facilities (3 acute care and 7 long-term care facilities) in

TABLE 2. RATES OF PARTICIPATION IN THE SURVEY OF THE PREVALENCE
VANCOMYCIN-RESISTANT ENTEROCOCCI BY FACILITIES IN THE SIOUXLAND REGION
IN JULY AND AUGUST 1997, OCTOBER 1998, AND OCTOBER 1999.*

OF

FACILITY

1997
NO.
ELIGIBLE

All
Acute care
Long-term care

2266
286
1980

1998
NO.

CULTURED

NO.

(%)

1934 (85)
152 (53)
1782 (90)

ELIGIBLE

2196
315
1881

1999
NO.

CULTURED

NO.

(%)

1954 (89)
165 (52)
1789 (95)

ELIGIBLE

2049
289
1760

NO.
CULTURED

(%)

1820 (89)
170 (59)
1650 (94)

*A total of 32 facilities (4 acute care and 28 long-term care facilities) participated in the 1997 and
1998 surveys, and a total of 30 facilities (4 acute care and 26 long-term care facilities) participated
in the 1999 survey.
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TABLE 3. PREVALENCE OF COLONIZATION WITH VANCOMYCIN-RESISTANT ENTEROCOCCI AMONG PATIENTS OR RESIDENTS
OF 30 ACUTE CARE AND LONG-TERM CARE FACILITIES IN THE SIOUXLAND REGION IN JULY
AND AUGUST 1997, OCTOBER 1998, AND OCTOBER 1999.*

TYPE

OF

FACILITY

COLONIZATION

WITH

VRE

1998

VERSUS

1997

1997

1998

1999

(95% CI)

1999

VERSUS

1998

RELATIVE RISK

RELATIVE RISK

P

VALUE

(95% CI)

1999

VERSUS

1997†

RELATIVE RISK

P

VALUE

(95% CI)

P

VALUE

no. of patients (%)

All
Acute care
Long-term care

40 (2.2) 26 (1.4) 9 (0.5)
10 (6.6) 9 (5.5) 0
30 (1.7) 17 (1.0) 9 (0.5)

0.6 (0.4–1.1)
0.8 (0.4–2.0)
0.6 (0.3–1.0)

0.08
0.67
0.05

0.4 (0.2–0.8)
0
0.6 (0.2–1.3)

0.005
0.002
0.14

0.2 (0.1–0.5) <0.001
0
<0.001
0.3 (0.2–0.7)
0.001

*Only data from the 30 facilities that participated in all three years of the study were included. VRE denotes vancomycin-resistant enterococci, and CI confidence interval.
†The results of the chi-square test for trend for the overall rates for 1997, 1998, and 1999 were also significant (P<0.001).

1998 and only 5 facilities (all long-term care facilities) in 1999 had at least one patient with vancomycinresistant enterococci. In 1999, among the 17 patients
with vancomycin-resistant enterococci in a long-term
care facility who had been identified in the 1998 survey, 12 (71 percent) had died and 1 (6 percent) had
been discharged from the facility.
Case–Control Study of Risk Factors for Colonization

In the 1998 case–control study, we compared 29
patients with vancomycin-resistant enterococci (from
all 32 participating facilities) with 114 controls. When
we analyzed acute care facilities, patients were significantly more likely than controls to have been in the
hospital at least 3 days, to have had at least one hospital admission in the 6 months before the study, to
have received a single type of antimicrobial agent for
at least 14 days, to have received an extended-spectrum cephalosporin, to have had diarrhea, and to have
had a urinary catheter (Table 4). Only one patient,
a control, had received intravenous vancomycin.
When we compared long-term care facilities, we
found that patients were significantly more likely than
controls to have been admitted to a hospital in the
six months before the study, to have been admitted
to hospital A (the acute care facility that had the
highest prevalence of vancomycin-resistant enterococci in the 1997 survey), and to have been treated
with an antimicrobial agent in the six months before
the study (Table 5). None of the patients or controls
in long-term care facilities had received vancomycin
in the previous six months.
Of the two patients in a long-term care facility
who had no prior hospital admission within the 12
months before the 1998 study, one had been admitted from a hospital before the 1997 study and had
had urinary colonization with vancomycin-resistant
enterococci before being transferred. Only one set of
two patients newly identified in 1998 were in adjoin-

ing rooms at one long-term care facility; no newly
identified patients with colonization or infection were
in the same room.
Evaluation of Infection-Control Policies

We received infection-control questionnaires from
all 32 facilities in 1998 and from 29 of 30 facilities in
1999 (97 percent). In 1998, we visited 3 of 4 acute
care facilities (75 percent) and 27 of 28 long-term
care facilities (96 percent). In 1998, 24 of 32 facilities
(75 percent) reported ever having had a patient who
was colonized with vancomycin-resistant enterococci:
3 of 4 acute care facilities (75 percent) and 21 of 28
long-term care facilities (75 percent). By 1999, 26
of 29 facilities (90 percent) reported ever having had
such a patient: all 4 acute care facilities (100 percent)
and 22 of 25 long-term care facilities (88 percent).
Screening and Identification of Colonized Patients
with Vancomycin-Resistant Enterococci

In 1997, the screening policies of acute care facilities were not assessed. In 1998 and 1999, all four
acute care facilities reported that they used aggressive screening policies, which included screening patients at high risk, such as those undergoing hemodialysis or in intensive care units; screening patients
on wards where clusters of colonization of infection
with vancomycin-resistant enterococci had occurred;
and screening all patients before they were discharged
to a long-term care facility. In 1997, only 9 of 28
long-term care facilities (32 percent) had a policy regarding screening for vancomycin-resistant enterococci. In contrast, in 1998 and 1999, more than 90
percent reported having such a policy (26 of 28 [93
percent] and 23 of 25 [92 percent], respectively).
For both acute care and long-term care facilities,
the proportion of all patients who were colonized
with vancomycin-resistant enterococci who were identified by screening was significantly higher in 1998
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TABLE 4. POTENTIAL RISK FACTORS FOR COLONIZATION WITH VANCOMYCIN-RESISTANT
ENTEROCOCCI IN ACUTE CARE FACILITIES.

POTENTIAL RISK FACTOR

PATIENTS WITH
COLONIZATION
(N=9)

CONTROLS
(N=32)

MATCHED ODDS RATIO
(95% CI)*

P VALUE

9 (100)
9 (100)

13 (41)
16 (50)

Undefined
Undefined

0.006
0.03

2 (22)
6 (67)

0
3 (9)

Undefined
14.1 (3.1–63.8)

0.05
0.001

3 (33)
4 (44)

2 (6)
2 (6)

16.5 (1.7–164)
14.3 (1.3–137)

0.006
0.01

1
0–33

—

0.003

Categorical variables
Exposure to health care facility — no. (%)
Length of stay »3 days
Prior hospital admission (within 6 mo)
Exposure to antimicrobial agents
Treatment with a single agent for »14 days
Treatment with extended-spectrum cephalosporin
Clinical factors
Diarrhea
Urinary catheter
Continuous variables
Total days of treatment with antimicrobial agents†
Median
Range

12
0–37

*Odds ratios were derived from a Mantel–Haenszel procedure, with each facility considered as a stratum (i.e., each
patient was matched to a control from the same facility). CI denotes confidence interval.
†The Kruskal–Wallis nonparametric test (not matched) was used.

TABLE 5. POTENTIAL RISK FACTORS (CATEGORICAL VARIABLES) FOR COLONIZATION
WITH VANCOMYCIN-RESISTANT ENTEROCOCCI IN LONG-TERM CARE FACILITIES.
PATIENTS WITH
COLONIZATION CONTROLS
(N=20)
(N=82)

POTENTIAL RISK FACTOR

MATCHED ODDS RATIO
(95% CI)*

P VALUE

no. (%)

Prior hospital admission (within 6 mo)
Prior admission to hospital A†
Length of stay <6 mo before positive
culture obtained
Treatment with antimicrobial agent
within preceding 6 mo

15 (75)
9 (45)
8 (40)

28 (34)
7 (9)
18 (22)

5.9 (1.7–20.8)
41.2‡
2.4 (0.9–4.7)

0.003
<0.001
0.08

18 (90)

55 (67)

4.6 (1.1–20.4)

0.04

*Odds ratios were derived from a Mantel–Haenszel procedure, with each facility considered as a
stratum (i.e., each patient was matched to a control from the same facility). CI denotes confidence
interval.
†Hospital A is the acute care facility that had the highest rate of vancomycin-resistant enterococci
in the 1997 prevalence survey.
‡Matched confidence intervals could not be calculated.

than in 1997 (for acute care facilities, 0 of 10 in 1997
vs. 9 of 9 in 1998, P<0.001; for long-term care facilities, 7 of 30 in 1997 vs. 10 of 20 in 1998, P=
0.05; data were available for 32 facilities in 1997 and
1998; data were unavailable for 1999).
Infection-Control Practices

Information about policies regarding the isolation
of patients who were positive for vancomycin-resistant enterococci, the recommended precautions to take

in caring for such patients, and the degree to which
the policies and procedures were enforced in 1997
was mainly anecdotal. In 1998 and 1999, all 4 acute
care facilities reported following the CDC recommendations,12 and most of the long-term care facilities that responded to our questions indicated that
they isolated patients who were positive for vancomycin-resistant enterococci or grouped them together (21 of 23 in 1998 [91 percent]; 22 of 25 in 1999
[88 percent]). In 1999, 2 of the 22 long-term care
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facilities with policies (9 percent) required patients
who were positive for vancomycin-resistant enterococci to be isolated in their rooms at all times and staff
members to adhere strictly to contact precautions.
Twenty long-term care facilities (91 percent) modified
the CDC recommendations by allowing such patients
to go outside their rooms for individual or group activities if they were capable of washing their hands
and either were continent of stool or had their body
fluids contained; providing ways to clean equipment
used by these patients outside their rooms, such as
wheelchairs; or encouraging the use of waterless hand
sanitizers for workers and patients in lieu of stringent isolation.
Use of Antimicrobial Agents

Among patients in long-term care facilities, a median of 8 percent in 1998 (range, 0 to 18 percent) and
7 percent in 1999 (range, 2 to 23 percent) had been
treated with antimicrobial agents within the week before the infection-control visit. Data on the use of
intravenous vancomycin that were provided by one
acute care facility in Sioux City showed a decrease in
vancomycin use from 1997 (483 of 11,658 admissions [4.1 percent]) to 1998 (383 of 11,677 admissions [3.3 percent], P<0.001).
Molecular Epidemiologic Findings

Genomic typing by pulsed-field gel electrophoresis was performed on 25 of 26 isolates of vancomycinresistant enterococci (96 percent) obtained in 1998
and all 9 obtained in 1999. Four genotypes accounted
for all 40 of the isolates obtained in 1997,10 as compared with 10 genotypes for the 25 isolates obtained
in 1998 and 7 genotypes for the 9 isolates obtained
in 1999. In 1997, one clone, type A, predominated
and accounted for 85 percent of the isolates. In 1998,
type A accounted for 58 percent of the isolates, and
in 1999, type A was not identified.
From the 1996 and 1997 isolates of vancomycinresistant enterococci obtained from three large referral
medical centers in the midwestern United States, one
isolate from a facility in Iowa approximately 480 km
(300 mi) from Sioux City was indistinguishable from
type A. Isolates from the two other referral centers
were not related to any of our Siouxland isolates.
DISCUSSION

In July and August 1997, we evaluated the extent
of colonization with vancomycin-resistant enterococci
among patients in 32 health care facilities in the
Siouxland District Health Department. Because of
the rapid emergence of vancomycin-resistant enterococci in 1997, a variety of control measures were implemented. In October 1998 and October 1999, we
returned to evaluate the effect of the intervention.
Virtually all published reports support the hypotheses that once vancomycin-resistant enterococci are

introduced, the rates of colonization and infection increase and vancomycin-resistant enterococci become
endemic unless effective control measures are introduced.2,6,9 Thus, without intervention, the prevalence of vancomycin-resistant enterococci in Siouxland health care facilities would have been expected
to increase. Instead, the overall rate of colonization
decreased from 2.2 percent in 1997 to 0.5 percent in
1999 at the 30 facilities that participated in all three
years of the study.
In 1995, the CDC published recommendations to
prevent the emergence and spread of vancomycinresistant enterococci that included the identification
and isolation of patients colonized with vancomycinresistant enterococci, hand washing by health care
workers, and cleaning of the environment.12 These
recommendations were written specifically for acute
care facilities and may need to be modified for longterm care facilities. We found increases in the screening
of patients and compliance with recommended precautions in facilities of the Siouxland District Health
Department in 1998 and 1999 as compared with
1997. Despite variations in the application of the CDC
recommendations at long-term care facilities, most patients who were colonized with vancomycin-resistant
enterococci who were identified in our prevalence
survey had already been identified by screening programs at the various facilities. By following the CDC
recommendations, these health care facilities were able
to turn the tide and reduce in long-term care facilities or eliminate in acute care facilities the transmission of vancomycin-resistant enterococci. They have
also prevented the emergence of serious infections
with vancomycin-resistant enterococci, as evidenced
by the fact that there have been no bloodstream or
invasive infections with vancomycin-resistant enterococci in these facilities since the intervention. In addition, the collaboration among the facilities has fostered
communication and eased the transfer of patients colonized with vancomycin-resistant enterococci between
facilities, in contrast to the usual limitation of access
for such patients.
The risk factors for colonization with vancomycinresistant enterococci in both 1997 and 1998 were the
use of antimicrobial agents and prior exposure to acute
care facilities.10 The rate of use of vancomycin in
these facilities is low and may have decreased further
since the intervention by the task force.
There are several limitations to our study. Cultures were obtained from a smaller proportion of patients in acute care facilities than in long-term care
facilities, which may have limited assessment of the
prevalence of vancomycin-resistant enterococci in
these facilities. However, participation rates were
similar in 1997, 1998, and 1999, and cultures were
obtained from most patients at high risk. In the only
acute care facility that had closed a unit because of
infections with vancomycin-resistant enterococci in
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early 1997, cultures were obtained from 89 percent
of patients.
We were able to perform all three evaluations in
only 30 of the 32 facilities. However, the two longterm care facilities that did not participate in all three
surveys had only about 100 residents.
As with any perianal screening for vancomycinresistant enterococci, colonization of some patients
may not be detected by only one swab. However, the
medium we used is part of a validated method of
screening for vancomycin-resistant enterococci and
is the same medium that is used by the laboratories
of the participating facilities and that is recommended by the CDC for screening.12
In conclusion, we evaluated the efficacy of an infection-control strategy in an entire region that was
implemented in order to prevent the emergence of
an antimicrobial-resistant pathogen. The success of the
intervention resulted from the collaboration among
the participating health departments, the Siouxland
District Health Department, and the personnel of the
health care facilities. In an era of emerging antimicrobial resistance, when many facilities are abandoning
efforts to control transmission, especially of vancomycin-resistant enterococci and methicillin-resistant
Staphylococcus aureus, this comprehensive, communitywide health care effort should be viewed as a model
for action. Our data show that comprehensive efforts
to identify and isolate patients who are colonized with
vancomycin-resistant enterococci can reduce the transmission of these strains and even eradicate them.
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